Theromin
Non-hirudin thrombin inhibitor from the rhynchobdellid leech Theromyzon tessulatum — highest-affinity natural inhibitor identified in a non-Hirudo species.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Non-hirudin thrombin inhibitor from the rhynchobdellid leech Theromyzon tessulatum — highest-affinity natural inhibitor identified in a non-Hirudo species.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Theromin's in vitro thrombin inhibition kinetics do NOT establish clinical efficacy as an anticoagulant. No FDA-approved derivative exists; this species is not used in clinical hirudotherapy.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 6,500 Da
- Source species
- Theromyzon tessulatum
- Discovered
- 2000 · Salzet et al.
Biological Targets
- → thrombin (Factor IIa)
Key Citations
- Salzet M et al. (2000), J Biol Chem · PMID 10837466
- Salzet M et al. (1998), FEBS Lett
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.